First-Generation Anti-Obesity Medications.

Q3 Medicine Diabetes Spectrum Pub Date : 2024-11-15 eCollection Date: 2024-01-01 DOI:10.2337/dsi24-0003

Sarah R Barenbaum, Mohini Aras

引用次数: 0

Abstract

The development of second-generation anti-obesity medications (AOMs) has transformed the treatment of obesity. However, the first-generation AOMs are still essential tools in the treatment of obesity. The decision of which AOM to initiate must be individualized taking into account patient preference, safety, tolerability, cost, and supply.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

第一代抗肥胖药物。

第二代抗肥胖药物（AOMs）的发展改变了肥胖的治疗方法。然而，第一代AOMs仍然是治疗肥胖的重要工具。决定启动哪个AOM必须个体化考虑患者的偏好，安全性，耐受性，成本和供应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Diabetes Spectrum Medicine-Internal Medicine

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： The mission of Diabetes Spectrum: From Research to Practice is to assist health care professionals in the development of strategies to individualize treatment and diabetes self-management education for improved quality of life and diabetes control. These goals are achieved by presenting review as well as original, peer-reviewed articles on topics in clinical diabetes management, professional and patient education, nutrition, behavioral science and counseling, educational program development, and advocacy. In each issue, the FROM RESEARCH TO PRACTICE section explores, in depth, a diabetes care topic and provides practical application of current research findings.

期刊最新文献

First-Generation Anti-Obesity Medications. Future Medications for Obesity and Clinical Implications. Pediatric Obesity Treatment: Considerations for Diabetes Educators and Clinicians. Using Second-Generation Anti-Obesity Medications. A Focus on the Pharmacotherapy of Obesity.